Interestingly, we report that BC patients with high FXR expression have greater overall survival uniquely in ER− tumors and the basal-like subtype, but not in the less aggressive luminal A BC subtype or ER+ tumors, suggesting great potential for targeted approaches for subtypes in need of therapeutic advances. This evidence concerns the gene NR1H4 and breast cancer.